

Proceeding Paper

Cyclometallated Thiosemicarbazones Containing Fluorine Atoms: A Solubility Improvement †

Marcos Rúa-Sueiro *, Juan M. Ortigueira and José M. Vila

Department of Inorganic Chemistry, Faculty of Chemistry, University of Santiago de Compostela, Avda. das Ciencias s/n, 15782 Santiago de Compostela, Spain; juanm.ortigueira@usc.es (J.M.O.); josemanuel.vila@usc.es (J.M.V.)

* Correspondence: marcos.rua.sueiro@usc.es

† Presented at the 25th International Electronic Conference on Synthetic Organic Chemistry, 15–30 November 2021; Available online: <https://ecsoc-25.sciforum.net/>.

Abstract: A novel set of thiosemicarbazone palladacycles is discussed. The addition of a fluorine atom to the thiosemicarbazone ligand increases not only the solubility of the ligand itself, but also that of the ensuing cyclometallated complexes. Ligands are synthesized in acidic ethanolic solution, and then reacted with potassium tetrachloropalladate(II), to give the corresponding cyclopalladated compounds bearing a tetranuclear structure. Characterization will be carried by IR, ¹H NMR and ¹⁹F NMR spectroscopies.

Keywords: thiosemicarbazone; palladium; cyclometallation; fluor; solubility

Citation: Rúa-Sueiro, M.; Ortigueira, J.M.; Vila, J.M. Cyclometallated Thiosemicarbazones Containing Fluorine Atoms: A Solubility Improvement. *Chem. Proc.* **2021**, *3*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Julio A. Seijas

Published: 15 November 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cyclometallated compounds are of great relevance in biology [1,2] because they contain metal centers, such as palladium [3], platinum [4] or ruthenium [5], that have proved to be efficient anticancer agents. Furthermore, thiosemicarbazone ligands also possess certain biological activity [6,7], making these cyclometallated compounds an excellent choice for biological tests. The main problem of these compounds is their low solubility, being poorly soluble in water and common organic solvents, except DMSO, a solvent commonly used in these assays. Synthesis of more soluble complexes [8,9] is the main target in medicinal and biological chemistry.

In this research work, the synthesis and characterization of new cyclometallated compounds containing fluorine atoms in their structure, which leads to increased solubility, is discussed. Synthesis of thiosemicarbazone ligands is done in acidic ethanolic solution, unlike the usual synthesis in water [10–13] because of the increasing solubility, which makes these ligands water-soluble. Then, the ligands are reacted with a palladium salt in ethanol/water, to form the corresponding cyclometallated compounds with the thiosemicarbazone as a tridentate [C, N, S] ligands.

2. Experimental

2.1. Synthesis of Thiosemicarbazone Ligands

400 mg of 2-fluoroacetophenone and the corresponding amount of thiosemicarbazide (see Table 1) were added in 15 cm³ of ethanol, following the reaction shown in Scheme 1. 0.5 cm³ of concentrated hydrochloric acid were added, and the mixture was stirred at room temperature for 24 h. After that, the solvent was removed under reduced pressure and the residue was dried under vacuum.

Table 3. IR stretch data.

Compound	R	ν (C=N)	$\Delta\nu$ (C=N)	ν (N-H)	ν (C=S)
1a	H	1557	-	3254/3212/3146	825
2a	Me	1563	-	3285/3217	829
3a	Et	1566	-	3265/3206	833
4a	Ph	1552	-	3277/3240	831
1b	H	1525	32	3268/3161	-
2b	Me	1528	35	3226	-
3b	Et	1521	45	3201	-
4b	Ph	1520	32	3216	-

3.2. ^1H NMR Spectroscopy

The ^1H NMR spectra of thiosemicarbazones (see Figure 1) is in agreement with the formation of the ligands.




Figure 1. ^1H NMR spectrum of compound 4a in DMSO-d_6 .

^1H NMR spectra of cyclometallated compounds (see Figure 2) were not done in DMSO-d_6 , usual solvent for these complexes. Their high solubility allows to run the spectra in CDCl_3 .

The disappearance of the hydrazinic proton resonance and the *ortho* aromatic proton resonance in the cyclometallated compounds spectra is consequent on cyclometallation. A doublet for the MeCN group is due to the coupling with the fluorine atom.




Figure 2. ^1H NMR spectrum of compound 4b in CDCl_3 .

3.3. ^{19}F NMR Spectroscopy

One signal appears in the ^{19}F NMR spectra (see Figure 3). The downfield shift of the resonance confirms cyclometallation.




Figure 3. ^{19}F NMR stacked spectra in CDCl_3 of: (a) compound 4b and (b) compound 4a.

4. Conclusions

- ✓ Synthesis of fluorinated thiosemicarbazone ligands and cyclometallated tetranuclear compounds was accomplished.
- ✓ An increase in solubility was observed for thiosemicarbazone ligands, changing the solvent medium from water to ethanol.
- ✓ Also, an increase in the solubility of the cyclometallated compounds was observed, as shown by the ^1H NMR spectra in CDCl_3 .
- ✓ IR data confirm cyclometallation of the ligands in the thiolic form, and the C-H activation in the fluor-containing phenyl ring.
- ✓ ^1H NMR spectra confirm the expected results. The disappearance of the hydrazinic proton (NNH) and the multiplicity change in the aromatic protons agrees with complex formation, with the thiosemicarbazone acting as a tridentate [C, N, S] ligand.
- ✓ ^{19}F NMR spectra show the downfield shift of the fluorine resonance. This is caused by the ligand's cyclometallation.

Acknowledgments: The authors thank funding from Xunta de Galicia (Galicia, Spain) under the Grupos de Referencia program (GRC 2019/014).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Oliveira, C.G.; Romero-Canelón, I.; Coverdale, J.P.; Maia, P.I.S.; Clarkson, G.J.; Deflon, V.M.; Sadler, P.J. Novel tetranuclear Pd II and Pt II anticancer complexes derived from pyrene thiosemicarbazones. *Dalton Trans.* **2020**, *49*, 9595–9604.
2. Licona, C.; Delhorme, J.-B.; Riegel, G.; Vidimar, V.; Cerón-Camacho, R.; Boff, B.; Venkatasamy, A.; Tomasetto, C.; Gomes, P.d.S.F.C.; Rognan, D. Anticancer activity of ruthenium and osmium cyclometalated compounds: Identification of ABCB1 and EGFR as resistance mechanisms. *Inorg. Chem. Front.* **2020**, *7*, 678–688.
3. Mbugua, S.N.; Sibuyi, N.R.S.; Njenga, L.W.; Odhiambo, R.A.; Wandiga, S.O.; Meyer, M.; Lalancette, R.A.; Onani, M.O. New Palladium(II) and Platinum(II) Complexes Based on Pyrrole Schiff Bases: Synthesis, Characterization, X-ray Structure, and Anticancer Activity. *ACS Omega* **2020**, *5*, 14942–14954, doi:10.1021/acsomega.0c00360.
4. Zhang, S.; Yao, X.; Watkins, N.H.; Rose, P.K.; Caruso, S.R.; Day, C.S.; Bierbach, U. Discovery of a Chiral DNA-Targeted Platinum–Acridine Agent with Potent Enantioselective Anticancer Activity. *Angew. Chem. Int. Ed.* **2020**, *59*, 21965–21970, doi:10.1002/anie.202009983.
5. Karas, B.F.; Hotz, J.M.; Gural, B.M.; Terez, K.R.; DiBona, V.L.; Côte-Real, L.; Valente, A.; Buckley, B.T.; Cooper, K.R. Anticancer Activity and In Vitro to In Vivo Mechanistic Recapitulation of Novel Ruthenium-Based Metallodrugs in the Zebrafish Model. *Toxicol. Sci.* **2021**, *182*, 29–43, doi:10.1093/toxsci/kfab041.
6. Hager, S.; Pape, V.F.S.; Pósa, V.; Montsch, B.; Uhlík, L.; Szakács, G.; Tóth, S.; Jabronka, N.; Keppler, B.K.; Kowol, C.R.; et al. High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones. *Antioxid. Redox Signal.* **2020**, *33*, 395–414, doi:10.1089/ars.2019.7854.
7. Srishailam, K.; Ramaiah, K.; Reddy, K.L.; Reddy, B.V.; Rao, G.R. Synthesis and evaluation of molecular structure from torsional scans, study of molecular characteristics using spectroscopic and DFT methods of some thiosemicarbazones, and investigation of their anticancer activity. *Chem. Pap.* **2021**, *75*, 3635–3647, doi:10.1007/s11696-021-01595-x.
8. Tong, X.; Zhang, L.; Li, L.; Li, Y.; Yang, Z.; Zhu, D.; Xie, Z. Water-soluble cyclometalated Ir (III) complexes as carrier-free and pure nanoparticle photosensitizers for photodynamic therapy and cell imaging. *Dalton Trans.* **2020**, *49*, 11493–11497.
9. Pander, P.; Turnbull, G.; Zaytsev, A.V.; Dias, F.B.; Kozhevnikov, V.N. Benzannulation via the use of 1,2,4-triazines extends aromatic system of cyclometallated Pt(II) complexes to achieve candle light electroluminescence. *Dye. Pigment.* **2021**, *184*, 108857, doi:10.1016/j.dyepig.2020.108857.
10. Lata, D.; Teresa Pereira, M.; Ortigueira, J.M.; Martínez, J.; Bermúdez, B.; Fernández, J.J.; Vila, J.M. Thiosemicarbazone platinacycles with tertiary phosphines. Preparation of novel heterodinuclear platinum–tungsten complexes. *Polyhedron* **2012**, *41*, 30–39, doi:10.1016/j.poly.2012.04.015.
11. Lucio-Martínez, F.; Bermúdez, B.; Ortigueira, J.M.; Adams, H.; Fernández, A.; Pereira, M.T.; Vila, J.M. A Highly Effective Strategy for Encapsulating Potassium Cations in Small Crown Ether Rings on a Dinuclear Palladium Complex. *Chem. A Eur. J.* **2017**, *23*, 6255–6258, doi:10.1002/chem.201700597.
12. Antelo, J.M.; Adrio, L.; Pereira, M.T.; Ortigueira, J.M.; Fernandez, J.J.; Vila, J.M. Synthesis and Structural Characterization of Palladium and Platinum Bimetallic Compounds Derived From Bidentate P,S-Palladacycle Metallogligands. *Cryst. Growth Des.* **2010**, *10*, 700–708, doi:10.1021/cg901111u.
13. Huseynova, M.; Medjidov, A.; Taslimi, P.; Aliyeva, M. Synthesis, characterization, crystal structure of the coordination polymer Zn(II) with thiosemicarbazone of glyoxalic acid and their inhibitory properties against some metabolic enzymes. *Bioorganic Chem.* **2019**, *83*, 55–62, doi:10.1016/j.bioorg.2018.10.012.